Search

Meeting Coverage:

American Society of Retina Specialists Annual Meeting

ASRS: 2018

A Look at Treatment Burden Associated With Intravitreal Injections for DME

Nancy M. Holekamp, MD

Show Description +

Does the 0.2 µg/day fluocinolone acetonide implant (Iluvien, Alimera Sciences) decrease the treatment burden for patients with diabetic macular edema (DME)? Nancy M. Holekamp, MD, addresses this question.

Posted: 7/21/2018

Keywords:

ASRS Symposium

•

Diabetic macular edema, DME

•

Intravitreal Injection

Up Next

OCT-A in Pediatric Patients

OCT-A in Pediatric Patients

Lejla Vajzovic, MD

Key Points From the Phase 3 PANORAMA Study

Key Points From the Phase 3 PANORAMA Study

Charles C. Wykoff, MD, PhD, FACS

The Future of Global Trends in Retina

The Future of Global Trends in Retina

Ehab N. El Rayes, MD, PhD, Paul Hahn, MD, PhD

How Has the Value of Retinal Procedures Changed?

How Has the Value of Retinal Procedures Changed?

Pravin U. Dugel, MD, Timothy G. Murray, MD, MBA

Here's the DRIL

Here's the DRIL

Amy Babiuch, MD

Complications Associated With Nd:YAG Laser Vitreolysis

Complications Associated With Nd:YAG Laser Vitreolysis

Paul Hahn, MD, PhD

Early Signs of Efficacy for a Bioengineered RPE Patch

Early Signs of Efficacy for a Bioengineered RPE Patch

Amir H. Kashani, MD, PhD

Women in Retina

Women in Retina

Anne E. Fung, MD, Jennifer I. Lim, MD, Nancy M. Holekamp, MD

Surgical Repair of Macular Holes

Surgical Repair of Macular Holes

Raymond Iezzi, MD, MS

Head-to-Head Comparison for nAMD Treatment

Head-to-Head Comparison for nAMD Treatment

Arshad M. Khanani, MD

Highlights From the Phase 3 Chroma and Spectri Trials

Highlights From the Phase 3 Chroma and Spectri Trials

Carl D. Regillo, MD, FACS

Phase 1b-2 Results of a Novel Targeted Therapy for Treatment of Choroidal Melanoma

Phase 1b-2 Results of a Novel Targeted Therapy for Treatment of Choroidal Melanoma

Amy C. Schefler, MD, FACS

The ASRS Takes Vancouver

The ASRS Takes Vancouver

Timothy G. Murray, MD, MBA

A Role for Biosimilars in Retina?

A Role for Biosimilars in Retina?

Alay S. Banker, MD, Charles C. Wykoff, MD, PhD, FACS

Visual Acuity Outcomes in Patients With Persistent DME Receiving Adjunctive Therapy

Visual Acuity Outcomes in Patients With Persistent DME Receiving Adjunctive Therapy

Raj K. Maturi, MD

Back to All Videos

A Look at Treatment Burden Associated With Intravitreal Injections for DME

Nancy M. Holekamp, MD

Does the 0.2 µg/day fluocinolone acetonide implant (Iluvien, Alimera Sciences) decrease the treatment burden for patients with diabetic macular edema (DME)? Nancy M. Holekamp, MD, addresses this question.

Posted: 7/21/2018

Keywords:

ASRS Symposium

•

Diabetic macular edema, DME

•

Intravitreal Injection

Please log in to leave a comment.

More From ASRS: 2018 Coverage

A Role for Biosimilars in Retina?

A Role for Biosimilars in Retina?

Alay S. Banker, MD, Charles C. Wykoff, MD, PhD, FACS

Visual Acuity Outcomes in Patients With Persistent DME Receiving Adjunctive Therapy

Visual Acuity Outcomes in Patients With Persistent DME Receiving Adjunctive Therapy

Raj K. Maturi, MD

OCT-A in Pediatric Patients

OCT-A in Pediatric Patients

Lejla Vajzovic, MD

Key Points From the Phase 3 PANORAMA Study

Key Points From the Phase 3 PANORAMA Study

Charles C. Wykoff, MD, PhD, FACS

Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of ASRS: 2018.